

## **ImmunoGen, Inc. Announces Webcast of Presentation at the 18th Annual NewsMakers in the Biotech Industry Conference**

WALTHAM, Mass., Oct. 13, 2011 (GLOBE NEWSWIRE) -- [ImmunoGen, Inc.](http://www.immunogen.com) (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its presentation at the 18<sup>th</sup> Annual NewsMakers in the Biotech Industry conference at 10:30 am ET on October 21, 2011 will be webcast live.

The webcast of this presentation can be accessed live through the "Investor Information" section of the Company's website, [www.immunogen.com](http://www.immunogen.com); a replay of the presentation will be available at the same location for one week.

### **About ImmunoGen, Inc.**

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development and a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare Pharmaceuticals, Biotest, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at [www.immunogen.com](http://www.immunogen.com).

CONTACT: For Investors:

Carol Hausner

Executive Director, Investor Relations

and Corporate Communications

ImmunoGen, Inc.

(781) 895-0600

[info@immunogen.com](mailto:info@immunogen.com)

For Media:

Barbara Yates

The Yates Network

(781) 258-6153